Giving that all the women who were treated for breast cancer are at life-time risk for lymphedema, using assessment methods that can accurately identify true lymphedema cases among at-risk breast cancer survivors is of the ultimate importance for clinical practice. Perhaps, the most important contribution of our study was that it has provided evidence that, using a cutoff point of L-Dex ratio of >+7.1, cross-sectional assessment of BIA was able to discriminate at-risk breast cancer survivors and those with lymphedema.
Fu, M.R., et al., L-dex ratio in detecting breast cancer-related lymphedema: reliability, sensitivity, and specificity. Lymphology, 2013. 46(2): p. 85-96,